Preview

Медицинский вестник Юга России

Расширенный поиск

Факторы прогноза при ревматоидном артрите: современное состояние проблемы

Полный текст:

Аннотация

В последние годы пересмотрены основные подходы к диагностике и лечению ревматоидного артрита (РА). В современных клинических рекомендациях установлены более ранние показания для проведения ранней агрессивной терапии биологическими агентами (БА), в то же время популяция больных с РА неоднородна, имеются различные варианты течения заболевания. В обзоре рассматриваются современные представления о различных прогностических факторах (клинических, иммунологических, рентгенологических, генетических) при РА, применяющихся для оценки динамики заболевания, в том числе на фоне терапии БА.

Об авторах

С. П. Оранский
Кубанский государственный медицинский университет
Россия

кафедра факультетской терапии

350000, г. Краснодар, ул. Седина, 4



Л. Н. Елисеева
Кубанский государственный медицинский университет
Россия

кафедра факультетской терапии

350000, г. Краснодар, ул. Седина, 4



Р. А. Ханферян
Кубанский государственный медицинский университет
Россия

кафедра факультетской терапии

350000, г. Краснодар, ул. Седина, 4



И. Г. Малхасян
Кубанский государственный медицинский университет
Россия

кафедра факультетской терапии

350000, г. Краснодар, ул. Седина, 4



Список литературы

1. Maini R, St Clair EW, Breedveld F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group //Lancet. – 1999. – №354. – P. 1932–1939.

2. Klareskog L, van der Heijde D, de Jager JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial //Lancet. – 2004. – № 363. – P. 675–681.

3. O’Dell JR Treating of rheumatoid arthritis early: a window of opportunity? //Art. Rheum. – 2002. – № 46. – P. 283–285.

4. Lard LR, Visser H, Speyer I et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies //Am. J. Med. – 2001. – № 111. – P. 446–451.

5. Moreland LW, Bridges SL. Early rheumatoid arthritis: a medical emergency? //Am. J. Med. – 2001. – №111. – P. 498–500.

6. Kombe B EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) //Ann. Rheum. Dis. – 2007. – № 66. – P. 34–45.

7. Saag KG American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis // Arthritis Rheum. – 2008. – № 59. – P. 762–784.

8. Oilier WE What is the natural history of rheumatoid arthritis? // Best Pract. Res. Clin. Rheumatol. – 2001. – № 15. – P. 27–48.

9. Pincus T, Callahan LF What is the natural history of rheumatoid arthritis? //Rheum. Dis. Clin. North Am. – 1993. – № 19. – P. 123–151.

10. Goronzy JJ. Prognostic markers of radiographic progression in early rheumatoid arthritis //Arthritis Rheum. – 2004. – №50. – P. 43–54.

11. Visser H How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis //Arthritis Rheum. – 2002. – № 46. – P. 357–31.

12. Emery P Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis // Rheumatology (Oxford). – 2008. – №47. – P. 392–398.

13. Scott DL Prognostic factors in early rheumatoid arthritis // Rheumatology (Oxford). – 2000. – № 39 (Suppl. 1). – P. 24–29.

14. Aletaha D Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients //Arthritis Rheum. – 2007. – № 56. – P. 3226–3235.

15. Turesson C Incidence and predictors of severe extra-articular disease manifestations an early rheumatoid arthritis inception cohort //Ann. Rheum. Dis. – 2007. – № 66. – P. 1543–1544.

16. Йегер Л. Клиническая иммунология и аллергология: в 3-х то- мах. – Т. 2. – 2-е изд. – М.: Медицина, 1990. – 560 с.

17. Renaudineau Y, Jamin C, Saraux A et al. Rheumatoid factor on a daily basis //Autoimmunity. – 2005. – № 38. – P. 11–16.

18. Vittecoq O, Pouplin S, Krzanowska K et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients //Rheumatology (Oxford). – 2003. – № 42. – P. 939–946.

19. Van Boekel MA, Vossenaar ER, Van den Hoogen FH Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value //Art. Res. – 2002. – № 4. – P. 87–93.

20. Visser H Early diagnosis of rheumatoid arthritis //Best Pract&Res Clin Rheum. – 2005. – № 19. – P. 55–72.

21. Visser H, Gelinck LB, Kampfraath AH et al. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis //Ann Rheum Dis. – 1994. – №55. – P. 157–161.

22. Bobbio-Pallavicini F, Caporali R, Alpini C et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis //Ann Rheum Dis. – 2007. – № 66. – P. 302–307.

23. Bos WH, Bartelds GM, Wolbink GJ et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis //J. Rheumatol. – 2007. – №35. – P. 1972–1977.

24. Ates A, Kinikli G, Turgay M et al. Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study //Clin Rheumatol. – 2007. – №26. – P. 538–545.

25. Girbal-Neuhauser E, Durieux J.-J, Arnaud M et al. The epitops targeted by the rheumatoid arthritis – associated antifilaggrin autoantibodies are posttranslationally generated on variouse sites of (pro) filaggrin by deimination of arginine resides //J. Immunol. – 1999. – № 162. – P. 585–594.

26. Van Gaalen FA, Van Aken J, Huizinga TW. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis // Art. Rheum. – 2004. – № 50. – P. 2113–2121.

27. Raza K, Breese M, Nightingale P et al. Predictive value of antibodies to cyclic сitrullinated peptides in patients with very early inflammatory arthritis //J Rheumatol. – 2005. – № 32. – P. 231–238.

28. Serdaroglu M, Cakirbay H, Defer O et al. The association of anti- CCP antibodies with disease activity in rheumatoid arthritis // Rheumatol. Int. – 2008. – № 28. – P. 965–970.

29. Visser K, Verpoort KN, van Dongen H, et al.: Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recentonset arthritis //Ann Rheum Dis. – 2008. – № 67. – P. 1194–1195.

30. Bruns A, Nicaise-Roland P, Hayem G et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis //Joint Bone Spine. – 2009. – № 76. – P. 248–253.

31. Mathson L, Mullazei M, Wick MC et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides //Arthritis Rheum. – 2008. – № 58. – P. 36–45.

32. Ursum J, Nielen MMJ, van Schaardenburg D et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study //Arthritis Res. Ther. – 2008. – № 10:R12.

33. Innala L, Kokkonen H, Ericsson C et al. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides //J Rheumatol. – 2008. – № 5. – P.1002–1008.

34. Buch MH, Reece RJ, Quinn MA, et al.: The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab) //Rheumatology (Oxford). – 2008. – № 47. – P.1469–1475.

35. Fabre S, Dupuy AM, Dossat N, et al.: Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis //Clin Exp Immunol. – 2008. – № 153. – P. 188–195.

36. Smolen JS, Aletaha D, Grisar J, et al. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? //Arthritis Res Ther. – 2008. – № 10. – P.208.

37. Kavanaugh A, Rosengren S, Lee SJ, et al.: Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results //Ann Rheum Dis. – 2008. – № 67. – P. 402–408.

38. Vos K, Thurlings RM, Wijbrandts CA, et al.: Early effects of rituximab on the synovial cell infi ltrate in patients with rheumatoid arthritis //Arthritis Rheum. – 2007. – № 56. – P. 772–778.

39. Burgoyne CH, Field SL, Brown AK et al.: Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse //Ann Rheum Dis. – 2008. – № 67. – P. 750–757.

40. Green MJ, Gough AK, Devlin J et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis // Rheumatology (Oxford). – 2003. – № 42. – P. 83–88.

41. Landewe R, Geusens P, Boers M, et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis //Arthritis Rheum. – 2004. – № 50. – P. 1390–1399.

42. Haavardsholm EA et al. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression //Ann. Rheum. Dis. – 2008. – № 67. – P. 794–800.

43. McQueen FM, Benton N, Perry D et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis //Arthritis Rheum. – 2003. – № 48. – P. 1814–1827.

44. Mundwiler ML, Maranian P, Brown DH et al. The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study //Arthritis Res Ther. – 2009. – № 1:R94.

45. Reynolds PP et al. Prediction of erosion progression using ultrasound in established rheumatoid arthritis: a 2-year follow- up study //Skeletal Radio. – 2009. – № 38. – P. 473–478.

46. Calin A Destructive arthritis, rheumatoid factor, and HLA-DR4. Susceptibility versus severity, a case-control study //Arthritis Rheum. – 1989. – № 32. – P. 1221–1225.

47. Lee HS et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts //Arthritis Rheum. – 2007. – № 56. – P. 1745–1753.

48. Prots I et al. Association of the IL4R single-nucleotide polymorphism 150V with rapidly erosive rheumatoid arthritis // Arthritis Rheum. – 2006. – №54. – P. 1491–1500.


Рецензия

Для цитирования:


Оранский С.П., Елисеева Л.Н., Ханферян Р.А., Малхасян И.Г. Факторы прогноза при ревматоидном артрите: современное состояние проблемы. Медицинский вестник Юга России. 2011;(1):18-22.

For citation:


Oranskiy S.P., Yeliseyeva L.N., Khanferyan R.A., Malhasyan I.G. Prognostic factors in patients with rheumatoid arthritis: current stage of a problem. Medical Herald of the South of Russia. 2011;(1):18-22. (In Russ.)

Просмотров: 135


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2219-8075 (Print)
ISSN 2618-7876 (Online)